HAYA Therapeutics Named a 2025 Technology Pioneer by the World Economic Forum
Share this article
HAYA Therapeutics, a Biopôle Lausanne based startup has been selected as one of the 100 early-stage companies in the World Economic Forum’s 2025 Technology Pioneers cohort!
This prestigious recognition highlights the company’s pioneering work in developing next-generation, disease-modifying precision medicines. HAYA is harnessing the power of the human genome’s dark matter to create precise RNA-based therapies that reprogramme disease-driving cell states — addressing the root causes of chronic and degenerative diseases. Its proprietary regulatory genome platform is opening new frontiers in cell-state biology and RNA therapeutics.
During the past few months, HAYA Therapeutics announced a one billion dollars agreement with the American biotech company Elli Lilly as well as a CHF 65 million Series A fundraising.
The WHO 2025 Technology Pioneers represent 28 countries and a growing wave of frontier technologies beyond traditional innovation hubs. The awardees are shaping the future of health, science, and society. Another Swiss, and Vaud-Based company, was also selected: Neural Concept.
➡️ Source: Press Release